Abstract Book 2010 - CIMT Annual Meeting
Abstract Book 2010 - CIMT Annual Meeting
Abstract Book 2010 - CIMT Annual Meeting
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
<strong>Abstract</strong> Nr. Title<br />
L124 Zhang<br />
031 Gross<br />
032 Zelba<br />
033 Singh<br />
034 Guidoboni<br />
035 Voland<br />
036 Wagner<br />
037 Aarntzen<br />
038 Moodie<br />
039 Attig<br />
040 Kotsiou<br />
Goal of ELISPOT proficiency accomplished: ELI-<br />
SPOT assays provide reproducible results among<br />
different laboratories for T-cell immune monitoring<br />
— even in hands of ELISPOT novices<br />
Monitoring of vaccine-specific regulatory and helper<br />
CD4+ and cytolytic CD8+ T cells after vaccination<br />
with autologous antigen-loaded dendritic cells<br />
NY-ESO-1-specific T cells in long-term melanoma<br />
survivors<br />
A stable standard sample for harmonisation and<br />
validation of T cell assay Satwinder Kaur Singh,<br />
Changes of immune cell infiltrates induced by dendritic<br />
cell vaccination in melanoma patients‘ tumor<br />
tissues: an immunohistochemical study<br />
Characterisation and functional analysis of T-cell<br />
responses in melanoma patients vaccinated with<br />
peptide-loaded dentritic cells<br />
GPI-anchor negative T cells with impaired effector<br />
function persist after Alemtuzumab mediated T-cell<br />
depletion<br />
skin-derived functional specific Tcells predict clinical<br />
outcome upon DC vaccination in stage III and<br />
IV melanoma patients<br />
Response definition criteria for ELISPOT assays<br />
revisited<br />
Recommendations for HLA-peptide multimer<br />
staining experiments - Results from the second<br />
HLA-peptide multimer proficiency phase organized<br />
by the Cancer Immunotherapy Consortium<br />
Application of MHC class I single chain trimers for<br />
leukaemia immunotherapy<br />
Poster session<br />
Immune monitoring I<br />
Immune monitoring II<br />
Immune monitoring II<br />
Immune monitoring II<br />
Immune monitoring II<br />
Immune monitoring II<br />
Immune monitoring II<br />
Immune monitoring II<br />
Immune monitoring II<br />
Immune monitoring II<br />
Cellular therapy I<br />
Oral short talk<br />
26.05.<strong>2010</strong>,<br />
16:05 – 16:20 hrs<br />
26.05.<strong>2010</strong>,<br />
16:05 – 16:20 hrs<br />
26.05.<strong>2010</strong>,<br />
16:05 – 16:20 hrs<br />
27
Change language